Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on ...

19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

澳大利亚墨尔本和美国新泽西州普林斯顿 - 专注于开发视网膜疾病治疗方法的生物制药公司Opthea Limited (ASX/NASDAQ: OPT)在同行评审期刊《转化视觉科学与技术》上发表了其sozinibercept治疗糖尿病黄斑水肿 (DME)的1b期试验结果。该研究评估了sozinibercept与标准抗VEGF-A疗法aflibercept联合使用在持续性DME患者中的安全性和有效性。

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

Pengana’s James McDonald is tipping into Aussie names Telix and Opthea, potash producer K+S, and the valuation case for Ardent at 70¢. The Carlyle Group and its newly acquired life sciences arm ...

Pre-Market: 7:35:01 a.m. EST ...

Opthea Limited, a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, announced that its CEO, Frederic Guerard, will present at the 43rd Annual J.P ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Opthea Limited has announced a change in the indirect interests of Director Lawrence Gozlan, who holds a ...

Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia ...

Research and development phase of new drugs for the treatment of eye diseases ...